Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy

References

• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Au JLS, Gunnarsson LC. (1989). Absorption of 5′-deoxy-5-fluorouridine from colon. Pharm Res 6:323–7
   PubMedGoogle Scholar
• Chabner BA. (1982). Primidine antagonist. In: Chapner BA, ed. Pharmacologic Principles of Cancer Treatment. Philadelphia, USA: Saunders, 132–42
   Google Scholar
• Chandrashekar NS, Shobha RRH. (2007). Cytotoxicity, antitumor activity, cumulative skin irritation and sensitization study of 5-fluorouracil from a transdermal patch for Dalton’s lymphoma ascites cells. J Health Sci 53:275–81
   Google Scholar
• Chang AYC, Most C, Pandya KJ. (1989). Continuous intravenous infusion of 5-FU in the treatment of refractory breast cancer. Am J Clin Oncol 12:453–5
   PubMed Web of Science ®Google Scholar
• Cheng SH, Scheule RK. (1998). Airway delivery of cationic lipid: DNA complexes for cystic fibrosis. Adv Drug Deliv Rev 30:173–84
   PubMed Web of Science ®Google Scholar
• Chew NYK, Chan HK. (2002). Effect of powder polydispersity on aerosol generation. J Pharm Sci 5:162–8
   Google Scholar
• Cortesi R, Esposito E, Gambarin S, et al. (1999). Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. J Microencapsul 16:251–6
   PubMed Web of Science ®Google Scholar
• Curreri A, Ansfield F, Mc-Iver F, et al. (1985). Clinical studies with 5-FU. Cancer Res 18:478–84
   Google Scholar
• Dijkstra J, Van Galen WJM, Hulstaert CE, et al. (1984). Interaction of liposomes with Kupffer cells in vitro. Exp Cell Res 150:161–76
   PubMed Web of Science ®Google Scholar
• Dine T, Kahlfi F, Duban M, et al. (1999). Effects of PVC bags sterilization process on the 5-fluorouracil stability. Biomaterials 20:655–61
   PubMedGoogle Scholar
• Dokka S, Toledo D, Shi X, et al. (2000). Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17:521–5
   PubMed Web of Science ®Google Scholar
• El Maghraby GMM, Williams AC, Barry BW. (2001). Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in vitro. J Pharm Pharmacol 53:1069–77
   PubMed Web of Science ®Google Scholar
• ElMeshad AN, Tadros MI. (2011). Transdermal delivery of an anti-cancer drug via w/o emulsions based on alkyl polyglycosides and lecithin: design, characterization, and in vivo evaluation of the possible irritation potential in rats. AAPSPharmSciTech 12:1–9
   PubMed Web of Science ®Google Scholar
• Elorza B, Elorza MA, Frutos G, Chantres JR. (1993). Characterisation of 5-fluorouracil loaded liposomes prepared by reverse-phase evaporation or freezing-thawing extrusion methods: study of drug release. Biochim Biophys Acta 1153:1335–42
   Google Scholar
• Elorza MA, Elorza B, Chantres JR. (1997). Stability of liposomal formulations: action of amphiphilic molecules. Int J Pharm 158:173–83
   Web of Science ®Google Scholar
• Fielding RM. (1991). Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetics and therapeutic perspective. Clin Pharmacokinet 21:155–64
   PubMed Web of Science ®Google Scholar
• Focan C, Kreutz F, Moeneclaye N, Focan-Henrard B. (2003). Randomised study to evaluate the chronotolerance of a combination infusional chemotherapy with 5-fluorouracil, folinic acid and caboplatin in non-small cell lung cancer (NSCLC) patients. Pathol Biol 51:204–5
   PubMedGoogle Scholar
• Fraile RJ, Baker LH, Buroker TR, et al. (1980). Pharmakokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223–8
   PubMed Web of Science ®Google Scholar
• Fresta M, Villari A, Puglisi G, Cavallaro G. (1993). 5-Fluorouracil: various kinds of loaded liposomes: encapsulation efficiency, storage stability and fusogenic properties. Int J Pharm 99:145–56
   Web of Science ®Google Scholar
• Ghussen F, Kruger I. (1989). Technical aspects of isolation extremity perfusion: experimental studies and clinical experience. J Invest Surg 2:487–96
   PubMedGoogle Scholar
• Gregoriadis G. (1991). Overview of liposomes. J Antimicrob Chemother 28:39–48
   PubMed Web of Science ®Google Scholar
• Hashizume H, Baluk P, Morikawa S, et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–80
   PubMed Web of Science ®Google Scholar
• Higuchi T. (1960). Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11:85–97
   Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Nat Acad Sci U S A 95:4607–12
   PubMed Web of Science ®Google Scholar
• Holland JF, Frei E, Bast RC Jr, et al. (1997). Cancer medicine. Philadelphia: Lea & Febiger
   Google Scholar
• Hughes GA. (2005). Nanostructure-mediated drug delivery. Nanomedicine 1:22–30
   PubMed Web of Science ®Google Scholar
• Kaiser N, Kimpfler A, Massing U, et al. (2003). 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment; entrapment and release properties. Int J Pharm 256:123–31
   PubMed Web of Science ®Google Scholar
• Kawashima Y. (2001). Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 47:1–2
   PubMed Web of Science ®Google Scholar
• Kemeny N, Huang Y, Cohen AM, et al. (1999). Hepatic arterial infusion of chemotherapy after resection of hepatic metastasis from colorectal cancer. N Eng J Med 341:2039–48
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Yamauchi H, Hirota S. (1994). A polyol dilution method for mass production of liposomes. J Liposome Res 4:71–91
   Web of Science ®Google Scholar
• Konduri KS, Nandedkar S, Duzgunes N, et al. (2003). Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 111:321–7
   PubMed Web of Science ®Google Scholar
• Lai YL, Mehta RC, Thacker AA, et al. (1993). Sustained bronchodilation with isoproterenol poly(glycolid-co-lactide) microspheres. Pharm Res 10:119–25
   PubMed Web of Science ®Google Scholar
• Langer R. (1998). Drug delivery and targeting. Nature 392:5–10
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
   PubMed Web of Science ®Google Scholar
• Markman M. (1996). Intraperitoneal therapy of ovarian cancer. Oncologist 1:18–21
   PubMedGoogle Scholar
• Markman M. (1999). Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 26:536–9
   PubMed Web of Science ®Google Scholar
• Marshall J, Yew NS, Eastman SJ, et al. (1999). Cationic lipid-mediated gene delivery to the airways. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego (CA): Academic Press, 39–68
   Google Scholar
• Mayhew E, Papahadjopoulos D. (1983). Therapeutic application of liposomes. In: Ostro MJ, ed. Liposomes. New York: Marcel Dekker, 289–41
   Google Scholar
• Mazumder A. (1981). Effect of liposome-entrapped 5-fluorouracil on Ehrlich ascites tumor bearing mice. Indian J Biochem Biophys 18:120–3
   PubMedGoogle Scholar
• McDonald DM, Baluk P. (2002). Significance of blood vessel leakiness in cancer. Cancer Res 62:5381–5
   PubMed Web of Science ®Google Scholar
• Meure LA, Foster NR, Dehghani F. (2008). Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech 9:798–809
   PubMed Web of Science ®Google Scholar
• Mozafari MR. (2005). Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 10:711–19
   PubMed Web of Science ®Google Scholar
• Mozafari MR, Mortazavi SM. (2005). Nanoliposomes: from fundamentals to recent developments. Oxford, UK: Trafford Publishing Ltd
   Google Scholar
• Mozafari MR, Pardakhty A, Azarmi S, et al. (2009). Role of nanocarrier systems in cancer nanotherapy. J Liposome Res. 19:310–21
   PubMed Web of Science ®Google Scholar
• Mozafari MR, Reed CJ, Rostron C, et al. (2002). Formation and characterisation of non-toxic anionic liposomes for delivery of therapeutic agents to the pulmonary airways. Cell Mol Biol Lett 7:243–4
   PubMed Web of Science ®Google Scholar
• Mozafari MR, Reed CJ, Rostron C, Hasirci V. (2005). A review of scanning probe microscopy investigations of liposome–DNA complexes. J Liposome Res 15:93–107
   PubMed Web of Science ®Google Scholar
• Muller H. (2002). Combined regional and systemic chemotherapy for advanced and inoperable non-small cell lung cancer. Eur J Surg Oncol 28:165–71
   PubMed Web of Science ®Google Scholar
• Nagahiro I, Mora BN, Boasquevisque CHR, et al. (2000). Toxicity of cationic liposome–DNA complex in lung isografts. Transplantation 69:1802–5
   PubMed Web of Science ®Google Scholar
• Nagayasu A, Uchiyama K, Kiwada H. (1999). The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 40:75–87
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. (1999). Niosomal delivery of 5-fluorouracil. J Microencapsul 16:731–40
   PubMed Web of Science ®Google Scholar
• Omidi Y, Barar J, Akhtar S. (2005). Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2:429–41
   PubMedGoogle Scholar
• Özer AY. (1992). Stability studies on 5-FU liposomes. Drug Target Deliv 1:151–60
   Google Scholar
• Özer AY, Talsma H. (1989). Preparation and stability of liposomes containing 5-FU. Int J Pharm 55:185–91
   Web of Science ®Google Scholar
• Patel VB, Basu S, Mandal S. (2011). Amphotericine B liposomal delivery system: preparation, characterization and release study. Int J Chem Anal Sci 2:97–102
   Google Scholar
• Peters GJ, Lankelma J, Kok RM, et al. (1993). Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 31:269–76
   PubMed Web of Science ®Google Scholar
• Reineccius G. (1995). Liposomes for controlled release in the food industry. In: Risch S, Reineccius G, eds. Encapsulation and Controlled Release of Food Ingredients. Washington DC: American Chemical Society, 113–31
   Google Scholar
• Rudy BC, Senkowski BZ. (1973). Fluorouracil. In: Florey K, ed. Analytical Profiles of Drug Substances. New York: Academic Press, 221–44
   Google Scholar
• Shan-Yang L. (1988). Effect of excipients on tablet properties and dissolution behavior of theophylene-tableted microcapsules under different compression forces. J Pharm Sci 77:229–32
   PubMedGoogle Scholar
• Sharma S, White D, Imondi AR, et al. (2001). Development of inhalational agents for oncologic use. J Clin Oncol 19:1839–47
   PubMed Web of Science ®Google Scholar
• Suarez S, O'Hara P, Kazantseva M, et al. (2001). Airways delivery of rifampicin microparticles for the treatment of tubercolosis. J Antimicrob Chemother 48:431–4
   PubMed Web of Science ®Google Scholar
• Triballier K, Dumouchel C, Cousin J. (2003). A technical study on the spraytec performances: influence of multiple light scattering and multi-modal drop-size distribution measurements. Exp Fluids 35:347–56
   Web of Science ®Google Scholar
• Tsukada S, Ueda S, Ukada R. (1984). Preparation of liposome encapsulated antitumor drugs relationship between lipophilicity of and in vitro drug release. Chem Pharm Bull 32:1929–35
   Web of Science ®Google Scholar
• Tuchman M, Stoeckeler JS, Kiang DT, et al. (1985). Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Eng J Med 313:245–9
   PubMed Web of Science ®Google Scholar
• Vemuri S, Rhodes CT. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 70:95–111
   PubMedGoogle Scholar
• Wagner JG. (1969). Interpretation of percent dissolved-time plots derived from in-vitro testing of conventional tablets and capsules. J Pharm Sci 58:1253–7
   PubMed Web of Science ®Google Scholar